ResultsIQ › Latest results › IPCA Laboratories Limited
IPCA Laboratories Limited Q2 FY27 earnings call summary
NSE: IPCALAB · BSE: 524494
Earnings call of 5 Nov 2026, summarised by AI from the filing.
Ipca's Q2 FY27 consolidated revenue rose around 14% to ₹2,910 cr with EBITDA margin at 22.97%, as FY27 guidance of 14-16% growth and 22-23% margin was reiterated.
Key takeaways
- Revenue Consolidated revenue ₹2,910 cr (Q2 FY26: ₹2,557 cr), growth of around 14%.
- Guidance FY27 growth guidance of 14% to 16% and consolidated EBITDA margin of 22% to 23% reiterated.
- Zerodol Zerodol umbrella brand crossed ₹1,500 cr per IQVIA, with similar growth expected for 3, 4 years.
- Costs Rising input, freight and energy costs, with air freight taking around ₹30 cr out of Unichem EBITDA.
IPCA Laboratories Limited Q2 FY27 results
As filed: Revenue ₹2,910 cr (+14% year on year), EBITDA ₹673 cr (+24% year on year), PAT ₹389 cr (+39% year on year), EBITDA margin 23.1% (+183 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹2,788 cr (+21% year on year), EBITDA ₹670 cr (+61% year on year), PAT ₹424 cr (+82% year on year), EBITDA margin 24.0% (+595 bps). Score 97 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 595 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹479 cr on a year ago, more than the ₹216 cr it added the year before. Share price after the results: +11.4% in 29 days (Nifty 500: −3.4%).
- Q4 FY26: Revenue ₹2,388 cr (+6% year on year), EBITDA ₹484 cr (+13% year on year), PAT ₹307 cr (+35% year on year), EBITDA margin 20.3% (+117 bps). Score 37 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit before exceptional items growth was in line with it. EBITDA margin rose 117 bps year on year. Revenue rose ₹141 cr on a year ago, against ₹214 cr the year before. Share price after the results: +2.9% in 27 days (Nifty 500: +0.6%).
- Q3 FY26: Revenue ₹2,393 cr (+7% year on year), EBITDA ₹533 cr (+15% year on year), PAT ₹364 cr (+32% year on year), EBITDA margin 22.3% (+167 bps). Score 42 of 100, In line with trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin rose 167 bps year on year. Revenue fell 6% from last quarter. Profit rose ₹87.7 cr on a year ago, more than the ₹55.0 cr it added the year before. Share price after the results: +6.0% in 28 days (Nifty 500: −9.6%).
- Q2 FY26: Revenue ₹2,557 cr (+9% year on year), EBITDA ₹545 cr (+23% year on year), PAT ₹281 cr (+30% year on year), EBITDA margin 21.3% (+255 bps). Score 41 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin rose 255 bps year on year. Revenue rose ₹202 cr on a year ago, against ₹321 cr the year before. Share price after the results: +12.6% in 29 days (Nifty 500: −0.4%).
- Q1 FY26: Revenue ₹2,309 cr (+10% year on year), EBITDA ₹417 cr (+6% year on year), PAT ₹233 cr (+17% year on year), EBITDA margin 18.1% (−67 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 67 bps year on year. Profit rose ₹34.0 cr on a year ago, against ₹35.0 cr the year before. Share price after the results: −5.3% in 30 days (Nifty 500: +2.8%).
- Q4 FY25: Revenue ₹2,247 cr (+11% year on year), EBITDA ₹429 cr (+33% year on year), PAT ₹64.0 cr (+56% year on year), EBITDA margin 19.1% (+325 bps). Score 35 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit before exceptional items growth was above it. EBITDA margin rose 325 bps year on year. Tax rate 48%. Consolidated profit +6300% but standalone -200%. Profit fell 10% from last quarter. Revenue rose ₹214 cr on a year ago, against ₹521 cr the year before. Share price after the results: −10.9% in 29 days (Nifty 500: +3.7%).
- Q3 FY25: Revenue ₹2,245 cr (+9% year on year), EBITDA ₹463 cr (+39% year on year), PAT ₹276 cr (+25% year on year), EBITDA margin 20.6% (+445 bps). Score 46 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin rose 445 bps year on year. Revenue fell 5% from last quarter. Revenue rose ₹192 cr on a year ago, against ₹507 cr the year before.
Past price moves after results do not indicate future moves. Not a recommendation.
IPCA Laboratories Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (5 Nov 2026)
- Q1 FY27: Earnings call (14 Aug 2026)
- Q4 FY26: Earnings call (1 Jun 2026)
- Q3 FY26: Earnings call (16 Feb 2026)
- Q2 FY26: Earnings call (13 Nov 2025), Results press release (13 Nov 2025)
- Q1 FY26: Earnings call (12 Aug 2025)
- Q4 FY25: Earnings call (30 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.